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ABSTRACT
Approximately 17% of the human genome is
comprised of long interspersed nuclear element 1
(LINE-1, L1) non-LTR retrotransposons. L1 retro-
transposition is known to be the cause of several
genetic diseases, such as hemophilia A, Duchene
muscular dystrophy, and so on. The L1 retroele-
ments are also able to cause colon cancer,
suggesting that L1 transposition could occur not
only in germ cells, but also in somatic cells if innate
immunity would not function appropriately. The
mechanisms of L1 transposition restriction in the
normal cells, however, are not fully defined. We here
show that antiretroviral innate proteins, human
APOBEC3 (hA3) family members, from hA3A
to hA3H, differentially reduce the level of L1 retro-
transposition that does not correlate either with
antiviral activity against Vif-deficient HIV-1 and
murine leukemia virus, or with patterns of
subcellular localization. Importantly, hA3G protein
inhibits L1 retrotransposition, in striking contrast to
the recent reports. Inhibitory effect of hA3 family
members on L1 transposition might not be due to
deaminase activity, but due to novel mechanism(s).
Thus, we conclude that all hA3 proteins act to
differentially suppress uncontrolled transposition of
L1 elements.
INTRODUCTION
Human APOBEC3G (hA3G) is known to be a powerful
innate antiretroviral factor, which can suppress Vif (virion
infectivity factor)-deﬁcient human immunodeﬁciency
virus type 1 (HIV-1) infection by deaminating viral
minus-strand DNA during reverse transcription, resulting
in G-to-A hypermutation (1–4). This cytidine deaminase
targets not only on retroviruses, such as simian immuno-
deﬁciency virus (5–8), primate foamy virus (9,10), human
T-cell leukemia virus type I (11) and murine leukemia
virus (MuLV (2,7,12)), but also on Hepatitis B virus
(13,14) which has a reverse transcription step. Recent
ﬁndings have revealed that hA3G also restricts transposi-
tion of murine MusD and intracisternal A-particle long
terminal repeat (LTR) retrotransposons (15). hA3G is one
of the APOBEC3 (A3) family containing A3A to A3H in
human. Vertebrates from ﬁsh to birds do not encode any
of A3 proteins (16), while mammals before primates
encode a single or two to three A3 proteins (17). Primates
have acquired seven tandem A3 genes throughout
33 million years of evolution (18), implying the ancient
history of battles between primates and retroelements.
In human genome, retrotransposons have accumulated
up to  42%, divided into two classes, which are non-
LTR, and LTR retrotransposons (19). Non-LTR types
are subdivided into long interspersed nuclear elements
(LINEs) and short interspersed nuclear elements (SINEs).
The most common human LINE, called LINE-1 (L1),
accounts for  17% of the human genome, corresponding
to 500000 copies, out of which 100 copies are known to be
full-length and transposition-competent (19–21). This
non-LTR retrotransposon is 6-kb long, and consists of
two open reading frames (ORFs) called ORF1 and ORF2
(22). ORF1 encodes an RNA-binding protein ORF1p
(23), and ORF2 encodes an enzymatic protein ORF2p like
Pol of retroviruses, carrying an endonuclease (24) and a
reverse-transcriptase (25,26), both of which are enzymat-
ically active. Importantly, L1 elements can cause several
genetic diseases by de novo L1 insertion at dispersed
positions in the germinal chromosomes, such as the
Factor VIII gene in patients with hemophilia A (27,28),
the Factor IX gene in patients with hemophilia B (29),
the dystrophin gene in patients with Duchene muscular
dystrophy (30,31), and with X-linked dilated cardiomy-
opathy (32), the b-globin gene in patients with b-thalas-
saemia (33), the CYBB gene in patients with chronic
granulomatous disease (34), and the RP2 gene in patients
with type-2 retinitis pigmentosa (35). The fact that colon
cancer is caused by L1 insertion into the APC genes of
somatic chromosomes (36), indicates that, L1 could be
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innate protection system would not work appropriately.
The mechanism by which L1 transpositions are restricted
in the normal cells, however, remains unknown.
Here we examined whether antiretroviral innate pro-
teins, human A3 (hA3) family members are able to show
inhibitory eﬀects on L1 retrotransposon. hA3 family, in
particular, hA3A, hA3B, hA3F and hA3G protein
expressions strongly decrease the transposition level of
L1 elements that does not correlate with either antire-
troviral activity or patterns of subcellular localization.
Results of DNA sequencing argue that inhibitory eﬀect of
hA3 family on L1 transposition might be independent of
deaminase activity. We conclude that all hA3 proteins are
able to diﬀerentially suppress uncontrolled transposition
of L1 retroelements.
MATERIALS AND METHODS
DNA constructs
The Vif-deﬁcient HIV-1 proviral indicator construct
pNL-Luc-F(-)E(-), and the L1 indicator constructs
pL1RP-EGFP (kindly provided by E.T. Luning Prak)
and pCEP4/L1mneoI/ColE1 (kindly provided by N.
Gilbert) have previously been described elsewhere
(37–39). Total RNA was isolated from H9 cells by using
RNAqueous Kit (Ambion), and was subjected to reverse
transcription, followed by ampliﬁcation with oligonucleo-
tides 50-GGG GTA CCA TGA ATC CAC AGA TCA
GAA ATC CG-30/50-ATT CTC GAG CTG GAG AAT
CTC CCG TAG CCT TC-30,5 0-GGG GTA CCA TGA
AGC CTC ACT TCA GAA AC-30/50-CCG CTC GAG
AAT CTC CTG CAG CTT GC-30,5 0-GGG GTA CCA
TGA AGC CTC ACT TCA GAA ACA-30/50-CCG CTC
GAG GTT TTC CTG ATT CTG GAG AAT-30 and
50-GGG GTA CCA TGG CTC TGT TAA CAG CCG
AAA CAT TCC G-30/50-CCG CTC GAG GGA CTG
CTT TAT CCT CTC AAG-30, producing hA3DE, hA3F,
hA3G or hA3H fragments, respectively. Total RNA
isolated from HeLa cells was subjected to RT-PCR
ampliﬁcation of hA3A, hA3B or hA3C genes using
oligonucleotides 50-ATG GTA CCA TGG AAG CCA
GCC CAG CAT C-30/50-CAT CTC GAG GTT TCC
CTG ATT CTG GAG AAT GG-30,5 0-GGG GTA CCA
TGA ATC CAC AGA TCA GAA ATC CG-30/50-CCG
CTC GAG GTT TCC CTG ATT CTG GAG AAT GG-
30,5 0-GGG GTA CCA TGA ATC CAC AGA TCA GAA
AC-30/50-ATT CTC GAG CTG GAG ACT CTC CCG
TAG CCT TC-30, respectively. Ampliﬁed hA3 fragments
were KpnI/XhoI-digested and cloned into a modiﬁed
mammalian expression plasmid pCAGGS carrying
carboxy-terminal hemaggulutinin (HA)-tag. To generate
an indicator retrovector construct pMSCVneo-Luc, a
luciferase gene from pGL4.10[luc2] vector (Promega)
was PCR-ampliﬁed by using oligonucleotides 50-GGA
ATT CGC CAT GGA AGA TGC CAA AAA CAT-30/
50-AAT CTC GAG TTA CAC GGC GAT CTT GCC
GCC C-30, digested with EcoRI and XhoI restriction
enzymes, and inserted into pMSCVneo (Clontech).
All constructs were veriﬁed by DNA sequencing.
Cell maintenance, transfections and proteinanalyses
HeLa cells, 293T cells and HT1080 cells were maintained
as described elsewhere (40,41). The human osteocarci-
noma 143BTK- cells were kindly provided by J. Hayashi
and cultured as previously described (42). 293T cells were
transfected with HA-tagged hA3 plasmids by using
FuGENE 6 transfection reagent (Roche) to conﬁrm hA3
protein expressions. Cell extracts from transfected cells are
subjected to western analysis using an anti-HA mouse
monoclonal antibody (Sigma). HeLa cells were transfected
with the same constructs by using Lipofectamine with
Plus reagents (Invitrogen) to determine subcellular local-
ization of hA3 proteins. Cells were ﬁxed, permeabilized
and incubated with an anti-HA monoclonal antibody and
Alexa 488 conjugating anti-mouse IgG (Invitrogen) used
for the ﬁrst and second antibodies, respectively.
Microscopic observation was performed by using
FV-1000 confocal microscopy (Olympus).
Viral infectivity assay
To prepare MuLV or HIV-1 supernatants, 7 10
5 293T
cells were cotransfected with 0.1mg of hA3 expression
plasmids and 0.1mg of VSV-G expression plasmid pHIT/G
(43), together with either 0.9mg of pMSCVneo-Luc
and 0.9mg of retroviral packaging vector pVPack-GP
(Stratagene), or 1mg of pNL-Luc-F(-)E(-) by using
FuGENE 6 and 0.8mg of an empty vector. Sixteen hours
later, cells were washed with phosphate-buﬀered saline, and
then 2ml of fresh complete medium was added. After 24h,
supernatants were harvested and treated with 37.5U/ml
DNase I (Roche) for 378C for 30min. HIV-1 supernatants
were subjected to measure p24 antigen by HIV-1
p24-antigen capture enzyme linked immunosorbent assay
(RETRO-TEK). To normalize MuLV supernatants,
transfected cells were lysed in 100ml of passive lysis buﬀer
(Promega), and ﬁreﬂy luciferase activities which indicate
transfection eﬃciencies were determined by Centro LB960
(Berthold). To determine the infectivity, 1 10
4 293T cells
were incubated with 0.1ng of p24 antigen of each HIV-1
or 100ml of normalized MuLV supernatants. After 48h,
cells were lysed in 100ml of lysis buﬀer, and ﬁreﬂy luciferase
activities were determined as described above.
L1retrotransposition assay
L1 retrotransposition assay was performed by cotransfec-
tion of 3.5 10
5 293T cells with 0.1mg of the respective
hA3 expression plasmids, 0.5mg of EGFP-based L1
reporter vector pL1RP-EGFP and 0.4mg of an empty
vector. Transfected cells were maintained by puromycin
treatment (0.5mg/ml) for 10 days. EGFP expression
resulting from retrotransposition was veriﬁed by ﬂow
cytometry. Another L1 retrotransposition assay was
performed by cotransfection of HeLa cells with equal
amounts of the respective hA3 expression plasmids and
neomycin-resistant (neo
r)-based L1 reporter vector
pCEP4/L1mneoI/ColE1, as previously described (15).
After 72h, cells were trypsinized, re-seeded onto 100mm
dishes for G418 (1mg/ml) selection and maintained.
Fourteen days after selection, resultant G418-resistant
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R) colonies were ﬁxed, stained with crystal violet
(Merck), and counted.
Confirmation of de novoL1 copynumber
Presumed copy number of retrotransposed L1 elements
was determined by real-time PCR targeting the EGFP
gene. Ten days after transfection as described above, total
cellular DNA was extracted from 293T cells by using
DNeasy kit (Qiagen) which is able to recover both
chromosomal and episomal DNA (according to the
manufacture’s manual). One hundred nanograms of each
DNA was subjected to real-time PCR detection using
oligonucleotides 50-GAA GAA CGG CAT CAA GGT
GAA C-30/50-GGT GCT CAG GTA GTG GTT GTC-30
and a probe 6-carboxyﬂuorescein (FAM)-50-AGC GTG
CAG CTC GCC GAC CA-30- black-hole quencher 1
(BHQ1). Real-time PCR was performed by using ABI
7900HT (ABI). L1 DNA levels are presented as copies per
10
4 cells.
Determination of endogenous levelsof L1and hA3mRNA
expressions in cell lines
Real-time RT-PCR was performed to quantify the
endogenous level of L1 and hA3 mRNA expression (and
of glyceraldehyde-3-phosphate-dehydrogenase [GAPDH]
mRNA expression as an internal control) in various cell
types. Total RNA was extracted from peripheral blood
lymphocytes (PBL; from two diﬀerent donors), 293T,
HeLa, HT1080 and 143BTK- cells, by using RNAqueous
Kit, and then, treated with TURBO DNA-free (Ambion)
according to the manufacturer’s protocols. Speciﬁc
oligonucleotides (o) and probes (p) used are as follows:
L1, (o) 50-GAG AAC AAA GAC ACC ACA TAC C-30/
50-GGC ATT TAG TGC TAT AAA TTT CCC -30 (p)
FAM-50-TCT CTG GGA CGC ATT CAA AGC AGT-30-
BHQ1; hA3A, (o) 50-CAC ACA TAT TCA CTT CCA
ACT TTA AC-30/50-GTC CAG GCG CTC CAC TTC-30
(p) FAM-50-CAT TGG AAG GCA TAA GAC CTA
CCT GTG C-30-BHQ1; hA3B, (o) 50-CGC TAA AGG
AGA TTC TCA GAT ACC-30/50-CAG GAC CCA GGT
GCC ATT G-30 (p) FAM-50-CCA GGC GCT CCA CCT
CAT AGC ACA-30-BHQ1; hA3C, (o) 50-CTG TGC TTC
ACC GTG GAA GG-30/50-TGA CAA TGG GTC TCA
GAA TCC AC-30 (p) FAM-50-AGC GCC GCT CAG
TTG TCT CCT GGA-30-BHQ1; hA3DE, (o) 50-ACC
GCA CGC TAA AGG AGA TTC-30/50-CGA CCA CAG
GCT TTC AGT AGG-30 (p) FAM-50-ACC CGA TGG
AGG CAA TGT ACC CAC AC-30-BHQ1; hA3F, (o) 50-
TGC CTT GGT ACA AAT TCG ATG AC-30/50-AGT
GGA AGT AGA ATA TGT GTG GAT AC-30 (p)
FAM-50-ATT CCT GCA CCG CAC GCT AAA GGA
GA-30-BHQ1; hA3G, (o) 50-GGC CGA GGA CCC GAA
GG-30/50-TTC TGA CAC AGG CTG CGA AG-30 (p)
FAM-50-CCC TGA CCA TCT TCG TTG CCC GCC-30-
BHQ1; hA3H, (o) 50-GGC TCA CGA CCA TCT GAA
CC-30/50-AGT CAG CAA ACT CTG GGA AGC-30 (p)
FAM-50-CGC CTC CCG CCT GTA CTA CCA CTG G-
30-BHQ1; GAPDH (o) 50-GAT GCT GGC GCT GAG
TAC G-30/50-GCA GAG ATG ATG ACC CTT TTG
G-30 (p) FAM-50-TGG AGT CCA CTG GCG TCT TCA
CCA CC-30-BHQ1. Oligonucleotide speciﬁcity for each
hA3 sequence was conﬁrmed by simultaneously using
all hA3 plasmids which gave no non-speciﬁc signals. L1
and hA3 mRNA levels were normalized with GAPDH
mRNA levels.
Sequencing ofde novo L1genes
Total cellular DNAs were isolated by using DNeasy
from the cells at 2 and 6 days after cotransfection of
pL1RP-EGFP with either an empty vector or hA3
constructs. Intronless EGFP DNAs were nested-PCR-
ampliﬁed by using PfxUltima (Invitrogen) and cloned into
pCR-Blunt vector using Zero Blunt PCR Cloning Kit
(Invitrogen). Sequencing was performed by using
ABI3130 (ABI).
RESULTS AND DISCUSSION
We ﬁrst examined if L1 is endogenously expressed in
primary and established cells. To do this, we performed
real-time RT-PCR targeting ORF1 gene, using total RNA
derived from two primary lymphocytes from diﬀerent
donors and from four diﬀerent established cell lines. As
shown in Figure 1, although the expression levels vary
among the cells tested, we found that all the cells express
L1 mRNA at the level of 10–100 copies/cell. The results
strongly emphasize that, even though L1 is expressed in
normal cells, its reverse transcription and integration
should be blocked by some innate protection system.
We therefore hypothesized that antiretroviral innate
proteins, hA3 family, might be eﬀective on L1 retro-
transposition as well as on that of mouse retroelements
(15).
To test this hypothesis, we created HA-tagged hA3
expression plasmids, using cDNA reverse-transcribed
from total RNA of H9 cells, or HeLa cells. Protein
expressions in the cells transfected with each plasmid were
conﬁrmed by immunoblotting using anti-HA antibodies
(Figure 2A). Using these plasmids, subcellular localization
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Figure 1. Endogenous expression of LINE-1 in primary and established
cells. LINE-1 mRNA copy numbers in PBL (two diﬀerent donors),
293T, HeLa, HT1080 and 143BTK- cells were determined by real-time
RT-PCR using total RNAs isolated from those cells. L1 mRNA levels
were normalized with GAPDH mRNA levels, and are presented as
copies per 10
4 cells.
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microscopy. As shown in Figure 2B, results were
consistent with the molecular size of each protein, i.e.
 46kDa proteins, which are larger than nuclear pore
exclusion limit (44), hA3DE, hA3F and hA3G proteins,
localized into the cytoplasm, while  23kDa proteins,
which are smaller than the limit, hA3A, hA3C and hA3H,
passively diﬀused into the nucleus. Although a larger
protein, hA3B was exceptionally found in the nucleus, this
localization is consistent with the recent report that hA3B
harbors a nuclear localization signal (45).
We next examined inhibitory eﬀects of hA3 family
proteins on Vif-deﬁcient HIV-1 and MuLV. Using virions
from the cells cotransfected with each virus construct and
hA3 expression plasmids, we determined infectivity
reduction by hA3 proteins. In accordance with the
previous reports (2,3,39,46–51), hA3B and hA3F as well
as hA3G revealed robust inhibitory activity on HIV-1,
while hA3C and hA3DE showed partial activity
(Figure 3A). MuLV infectivity was reduced by hA3B,
hA3C and hA3G protein expressions (Figure 3B), as
previously reported (2,49,50). Therefore, with respect to
the antiretroviral activity, we here conﬁrmed known
phenotypes of all hA3 family members as observed
in these experiments.
To determine if hA3 family members are able to inhibit
L1 retrotransposition, we ﬁrst employed EGFP-based
retrotransposition assay (38). In this assay system, we
utilized a L1 clone DNA carrying a reverse-oriented
EGFP gene separated by a gamma-globin intron, and also
carrying a puromycin resistance gene which allows
selection of transfected cells. After transfection of the
cells with this construct, followed by puromycin selection,
EGFP with L1 is transcribed, spliced, reverse-transcribed
and integrated. Then, the EGFP integrated with L1 is
driven by CMV promoter and expressed. In other words,
EGFP-positive cells are the cells in which L1
hA3A hA3B hA3C hA3DE hA3F hA3G hA3H
25
47
hA3H
C/N
Mo
hA3F
C
hA3G
C
hA3DE
C
hA3B
N
hA3A
C/N
hA3C
C/N
A
B
Figure 2. Western analysis and subcellular localization of the hA3
family proteins. (A) Western blot analysis was performed by using
extracts from 293T cells transfected with HA-tagged hA3 expression
plasmids. Antibodies speciﬁc for HA were used. (B) To analyze
subcellular localization of hA3 proteins, immunoﬂuorescence micro-
scopy was performed by using HeLa cells transfected with the HA-
tagged hA3 expression plasmids. An anti-HA monoclonal antibody and
Alexa 488 conjugating anti-mouse IgG were used for the ﬁrst antibody
and for the second antibody, respectively. C, N or C/N in the pictures
indicates cytoplasmic, nuclear or both localizations, respectively.
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Figure 3. Inhibitory eﬀect of hA3 family proteins on retroviruses. 293T
cells were cotransfected with VSV-G and hA3 expression plasmids,
together with a luciferase-based HIV-1 or MuLV construct. After 48h,
each viral supernatant was harvested. Normalized supernatants were
incubated with 293T cells for additional 48h. Cells were then lysed and
subjected to luciferase assay. Data shown are mean SD. RLU:
relative light units.
2958 Nucleic Acids Research, 2007, Vol. 35, No. 9retrotransposition successfully occurred. EGFP expres-
sion in cells cotransfected with each hA3 plasmid and the
L1-EGFP vector were visualized by microscopy
(Figure 4A), and quantitatively analyzed by ﬂow cytom-
etry (Figure 4B). Without coexpressions of hA3
proteins, L1 transposition normally occurred at the level
shown in the upper left panel of Figure 4. In contrast,
coexpressions of any of hA3 proteins diﬀerentially
inhibited L1 retrotransposition, and in particular, hA3A,
hA3B, hA3F and hA3G expressions strongly decreased
the transposition level of L1 elements to 0.9, 14.0, 15.6 and
10.2%, respectively. These activities against L1 did not
correlate with their patterns of subcellular localization
(Figure 2B) and inhibitory activities on retroviruses
(Figure 3A and B). In this assay, we observed no cytotoxic
eﬀect of A3 proteins (data not shown) as previously
reported (52,53).
To assess reproducibility of this experiment, we next
performed a diﬀerent type of retrotransposition assay,
using L1 vector which carries neo
r gene (37) instead of the
EGFP gene. In this assay, after neomycin selection
following transfection, we were able to quantify the
retrotransposition level, simply by counting G418
r
colonies. As shown in Figure 5A and B, this assay gave
results equivalent to that obtained with EGFP-based
assay. Thus, on the basis of the data presented here,
we conclude that all hA3 proteins act to diﬀerentially
suppress uncontrolled L1 retrotransposition. Importantly,
in striking contrast to the recent reports (45,53–56), we
observed the inhibitory eﬀect of hA3G proteins on
retrotransposition in both assays (Figures 4 and 5).
To conﬁrm that hA3G is indeed eﬀective on retro-
transposition inhibition, we next measured presumed copy
number of retrotransposed L1 elements by performing
real-time PCR using total DNA which was isolated from
the cells used in Figure 4. To exclude detection of genomic
DNA, we targeted intronless EGFP DNA which is
detectable only in spliced and reverse-transcribed L1
elements carrying the EGFP gene. As shown in
Figure 6, results obtained with this assay were fully
consistent with those observed in ﬂow cytometry analysis,
and in neo-resistance assay. We therefore conclude that
hA3G is indeed able to inhibit L1 retrotransposition as
well as hA3A, hA3B and hA3F. Importantly, the fact that
results shown in Figure 6 were obtained by detecting not
only integrants, but also reverse transcripts, and are
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Figure 4. EGFP-based retrotransposition assay. 293T cells were
cotransfected with the EGFP-based L1 retrotransposon indicator
construct pL1RP-EGFP and hA3 expression plasmids. After 48h, cells
were subjected to puromycin (0.5mg/ml) selection. After 8 days of
puromycin selection, cells were observed by ﬂuorescence microscopy
(A) and subjected to ﬂow cytometry analysis (B). Retrotransposition
level in the absence of hA3 proteins was set as 100%. Data shown are
mean SD;
 P50.05,
  P50.01,
   P50.001, t-test.
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Figure 5. neo
r-based retrotransposition assay. HeLa cells were cotrans-
fected with pCEP4/L1mneoI/ColE1 and the respective hA3 expression
plasmids. Seventy-two hours later, cells were trypsinized, re-seeded onto
100mm dishes, and subjected to G418 (1mg/ml) selection. Fourteen
days after selection, resultant G418
R colonies ﬁxed, stained with crystal
violet (A), and counted to determine the level of L1 retrotransposition
(B). Transposition level in the absence of hA3 proteins was set as
100%. Data shown are mean SD;
 P50.05,
  P50.01,
   P50.001,
t-test.
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EGFP expression represent L1 integrants, suggest that
hA3 proteins at least hA3A and hA3G suppress de novo
L1 DNA synthesis, but not integration.
To examine whether cytidine deamination would
explain the mechanism by which the retrotransposition
is inhibited, we sequenced L1 elements resulting from
retrotransposition which was reduced by hA3G protein.
We targeted intronless reverse-oriented EGFP genes for
the reason given above. Surprisingly, we observed only
one C-to-T mutation (G-to-A mutation on plus-strand
DNA) out of 4200bp nucleotide sequences (Figure 7). As
a control experiment, we analyzed deaminase activity of
hA3G on vif HIV-1 reverse transcripts by sequencing
the 30 end of env genes in infected cells. In contrast to
Figure 7, G-to-A mutations were found in 367 out of
5900bp in total (unpublished data). In other hA3 protein
expressions, we were not able to ﬁnd any mutation (0 out
of 25200bp, data not shown). These results suggest the
possibility that inhibitory eﬀect of hA3G on L1 retro-
transposition might be independent of its deaminase
activity as previously observed in studies of antiviral
phenotypes (11,13,57), but this needs to be elucidated with
further experiments using mutant hA3G, such as catalyt-
ically inactive mutants.
Finally, we performed real-time RT-PCR analysis to
determine endogenous expression levels of hA3 proteins in
various types of cells. As shown in Figure 8, we found that
the endogenous levels of hA3 expressions vary depending
on the cell types. Especially, some cell types abundantly
coexpress hA3B and hA3G proteins which are able
to eﬀectively suppress L1 transposition. Therefore, the
diﬀerent results in other studies might be due to
the diﬀerent cells used.
In this study, we ﬁrst presented evidence showing that
primary and established cells endogenously express L1
mRNA at the level of 10–100 copies/cell. Although
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Figure 6. Real-time PCR targeting spliced EGFP genes. Total cellular
DNA was extracted from the cells used in Figure 4 and subjected to
real-time PCR analysis. Dual labeled probe was designed for the
detection of spliced EGFP. Mock, hA3A and hA3G were shown as
representatives. Data shown are mean SD;
 P50.001, t-test.
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A3G-d2-#7   1:...................................................................................................................................................... 150
A3G-d6-#1   1:...................................................................................................................................................... 150
A3G-d6-#2   1:...................................................................................................................................................... 150
A3G-d6-#3   1:...................................................................................................................................................... 150
A3G-d6-#4   1:...................................................................................................................................................... 150
A3G-d6-#5   1:...................................................................................................................................................... 150
A3G-d6-#6   1:...................................................................................................................................................... 150
A3G-d6-#7   1:...................................................................................................................................................... 150
******************************************************************************************************************************************************
Reference 151:GGCCCACCCTCGTGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACA 300
A3G-d2-#1 151:...................................................................................................................................................... 300
A3G-d2-#2 151:...................................................................................................................................................... 300
A3G-d2-#3 151:...................................................................................................................................................... 300
A3G-d2-#4 151:...................................................................................................................................................... 300
A3G-d2-#5 151:...................................................................................................................................................... 300
A3G-d2-#6 151:...................................................................................................................................................... 300
A3G-d2-#7 151:...................................................................................................................................................... 300
A3G-d6-#1 151:...................................................................................................................................................... 300
A3G-d6-#2 151:........................T............................................................................................................................. 300
A3G-d6-#3 151:...................................................................................................................................................... 300
A3G-d6-#4 151:...................................................................................................................................................... 300
A3G-d6-#5 151:...................................................................................................................................................... 300
A3G-d6-#6 151:...................................................................................................................................................... 300
A3G-d6-#7 151:...................................................................................................................................................... 300 
************************.*****************************************************************************************************************************
Figure 7. Sequence analysis of L1 reverse transcripts. Total DNA was extracted from 293T cells cotransfected with pL1RP-EGFP and hA3 expression
plasmid, at 2 and 6 days after transfection. Reverse transcribed EGFP genes were PCR-ampliﬁed and inserted into the cloning vector. Alignment of
partial sequences of EGFP genes in hA3G-cotransfected cells is shown.
2960 Nucleic Acids Research, 2007, Vol. 35, No. 9we were unable to directly demonstrate endogenous
expressions of L1 proteins per se, many, if not most, of
L1 retroelements must be encoded from mRNA detected
in our experiments, and should be sensitive to some innate
immunity defenses. Otherwise, uncontrolled L1 transposi-
tion becomes obviously deleterious to the cells. Based on
the hypothesis that hA3 family proteins of human innate
antiretroviral factors might be the key to understanding
how transposition of L1 retroelements is naturally
inhibited in the cells, we preformed two diﬀerent types
of established retrotransposition assays using all hA3
(A, B, C, DE, F, G and H) expression plasmids. Results
obtained in these assays revealed diﬀerential inhibitory
eﬀect of all hA3 family member proteins on L1 retro-
transposition. However, we could not observe any
correlation between the levels of L1 transposition inhibi-
tion by hA3 and either their subcellular localization or
antiviral activities against retroviruses.
An intriguing ﬁnding in this study was that hA3G
was also identiﬁed as an intrinsic inhibitor of L1
retrotransposition. This ﬁnding was indeed reproducible
in two diﬀerent retrotransposition assays, and a real-time
PCR analysis. Sequence analysis, however, revealed no
DNA deamination eﬀect of hA3G on de novo L1
retrotransposons, strongly suggesting that cytidine
deaminase hA3G inhibits L1 transposition by novel
mechanism(s). Although we cannot rule out that hA3G
might deaminate L1 reverse transcripts which could result
in rapid degradation by cellular enzymes such as uracil
DNA glycosylase and would be therefore undetectable,
hA3G protein has been indeed found to have dual
inhibitory eﬀects on murine endogenous retroviruses,
which are G-to-A editing and reduction of viral cDNA
yields (58). Besides, antiretroviral function of hA3G has
been demonstrated to be dissociated from its deaminase
activity because deaminase mutants of hA3G still retained
antiviral activity (59–61). Taken together, it is likely that
hA3G could prevent L1 DNA synthesis per se. This still
needs to be elucidated.
Cytoplasmic expression of hA3G protein, as observed
in Figure 2B, has been thought to cause inaccessibility of
this protein to L1 reverse transcripts which are synthesized
in the nucleus, leading to the lack of inhibitory activity of
hA3G on L1 transposition (45,56). Yet, another cytoplas-
mic hA3 family protein hA3F is reported to be also active
on inhibition of L1 transposition (53,54), consistent with
that observed in our study. This discrepancy might be
explained by the mechanism of L1 replication as follows:
L1 DNA synthesis in the nucleus is based on ‘target-
primed reverse transcription’ in which reverse transcripts
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Figure 8. Endogenous expressions of hA3 family members in primary and established cells. Total RNAs were extracted from PBL (from two
diﬀerent donors), 293T, HeLa, HT1080 (HT) and 143BTK- cells, and subjected to real-time RT-PCR to determine the copy numbers of the
respective hA3 mRNAs. Levels of hA3 mRNA were normalized with GAPDH mRNA levels, and are presented as copies per 10
4 cells.
Nucleic Acids Research, 2007, Vol. 35, No. 9 2961are generated at L1 endonuclease-nicked chromosomal
DNA using polyadenylated L1 RNA as a template (62).
Importantly, at an early phase of replication before target-
primed reverse transcription, L1 forms a ribonucleopro-
tein complex as a retrotransposition intermediate by
associating its own encoding RNA with ORF1p and
ORF2p in the cytoplasm (63–66). At this step, cytoplasmic
hA3G protein as well as hA3F protein might be able to
ﬁnd a critical, if narrow, window of opportunity for access
to the L1 RNA complexed with ORF1p and ORF2p, since
hA3G is able to bind RNA nonspeciﬁcally (67). If this
is the case, hA3G (or hA3F) protein might be able to
enter the nucleus with the ribonucleoprotein complex in
which ORF2p harbors a putative nuclear localization
signal (68,69), and inhibit L1 reverse transcription
eﬀectively, by physically blocking the access of the
ORF2p to the nicked chromosomal DNA, or by hindering
the movement of the reverse transcriptase of ORF2p on a
template L1 RNA.
Turelli et al. (56) originally reported that hA3G does
not aﬀect L1 retrotransposition in the EGFP-based
retrotransposition assay which we also utilized in this
article. The cells used in their experiments, 143BTK-
osteocarcinoma cells, were found in our study to
endogenously coexpress high level of hA3B and hA3G
(Figure 8) which are able to eﬀectively inhibit LINE-1
transposition. It seems likely that coexpression of hA3B
and hA3G proteins might reduce the basal level of L1
retrotransposition. In fact, 143BTK- cells transfected with
the pL1RP-EGFP construct in our study showed only faint
EGFP signals (data not shown) compared with those in
293T cells, although transfection eﬃciencies were equiva-
lent in both the cells. Besides, reﬂecting phenotypes of
cells expressing hA3B and hA3G proteins, 143BTK- cells
transfected with an HIV-1 proviral construct with or
without an intact vif gene produced  50-fold less
infectious virions, than did 293T cells (unpublished
data). These virions showed no eﬀect of Vif protein on
infectivity rescue, just as described by Turelli et al. (56).
This could be due to that hA3B which can be incorporated
into virions as well as hA3G (48) might be more eﬀective
on inhibition of infection than does hA3G, leading to the
lack of Vif-negative phenotypes.
The cell-type preference of hA3 protein expressions,
however, might not be able to account for the results in
three other articles very recently published, showing
inability of hA3G to inhibit L1 transposition by using
neo
r-based L1 retrotransposition assay in HeLa cells
(45,53,55), as used in our study. A possible explanation
can be drawn from the fact that HeLa cells are
highly divergent (70) in which expression pattern of
hA3 proteins might diﬀer depending on derivatives of
this cell line. Overall, this preferential hA3 expression
in a cell type-dependent manner as observed in this
study [and also in a tissue-speciﬁc manner described in
other reports (1,17,46,48,49,51,71)] might explain the
diﬀerence of results obtained. It will be of interest to
further examine whether coexpression of hA3 proteins
are able to either additively or cooperatively inhibit
L1 retrotransposition.
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